FY2026 EPS Estimates for Exagen Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised Exagen's FY2026 earnings per share (EPS) estimates from ($0.31) to ($0.68), maintaining an "Overweight" rating and a target price of $10.00.
• The current consensus estimate for Exagen's full-year earnings is ($0.88) per share, reflecting ongoing challenges for the company.
• Despite the downgrade, multiple analysts have rated Exagen as a "buy" with an average price target of $11.25, indicating some level of confidence in the company's potential.

Exagen Inc. (NASDAQ:XGN - Free Report) - Equities research analysts at Cantor Fitzgerald dropped their FY2026 earnings per share (EPS) estimates for Exagen in a research note issued on Wednesday, July 30th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.68) per share for the year, down from their prior estimate of ($0.31). Cantor Fitzgerald currently has a "Overweight" rating and a $10.00 target price on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

Several other equities analysts have also weighed in on XGN. Craig Hallum initiated coverage on Exagen in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $12.00 price objective on the stock. BTIG Research reiterated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. KeyCorp upgraded Exagen from a "sector weight" rating to an "overweight" rating and set a $12.00 target price for the company in a research note on Wednesday. UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Finally, Canaccord Genuity Group increased their target price on Exagen from $8.00 to $11.00 and gave the company a "buy" rating in a research note on Wednesday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $11.25.

Exagen Stock Performance

NASDAQ XGN opened at $8.40 on Friday. Exagen has a fifty-two week low of $1.78 and a fifty-two week high of $9.10. The stock has a market cap of $184.80 million, a price-to-earnings ratio of -9.44 and a beta of 1.58. The business has a fifty day moving average of $7.15 and a 200-day moving average of $5.39. The company has a quick ratio of 2.32, a current ratio of 4.95 and a debt-to-equity ratio of 1.06.

Exagen (NASDAQ:XGN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million. Exagen had a negative return on equity of 130.38% and a negative net margin of 28.85%.

Hedge Funds Weigh In On Exagen

Several large investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in Exagen in the 1st quarter valued at approximately $25,000. Corient Private Wealth LLC acquired a new stake in Exagen during the fourth quarter valued at approximately $45,000. Marshall Wace LLP acquired a new position in shares of Exagen in the 4th quarter worth approximately $66,000. Northern Trust Corp lifted its position in shares of Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares during the period. Finally, Huntleigh Advisors Inc. boosted its stake in Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock valued at $298,000 after buying an additional 11,939 shares in the last quarter. Institutional investors and hedge funds own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.